Nguyen Dang Tu Le
Biographic Data
| ID | 10001793 |
|---|---|
| NAME | Nguyen Dang Tu Le |
| GIVEN NAMES | Nguyen Dang Tu |
| FAMILY NAME | Le |
| SIGNATURE | LE N D T |
| AFFILIATIONS | University of Medicine and Pharmacy at Ho Chi Minh City |
| ORCID | 0000-0002-4233-4696 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2020 |
| H-INDEX | 0 |
Cost-Effectiveness of Gliclazide-Based Intensive Glucose Control vs. Standard Glucose Control in Type 2 Diabetes Mellitus. An Economic Analysis of the Advance Trial in Vietnam
Introduction: ADVANCE was a large, multinational clinical study conducted over 5 years in type 2 diabetes mellitus (T2DM). In all, 11,140 patients were randomly assigned to receive gliclazide-based intensive glucose control (IGC) or standard glucose control (SGC). IGC was shown to significantly reduce the incidence of major macrovascular and microvascular events (composite endpoint) or major microvascular events compared with SGC, primarily by en…
No prominent works on this page.
Cost-Effectiveness of Gliclazide-Based Intensive Glucose Control vs. Standard Glucose Control in Type 2 Diabetes Mellitus. An Economic Analysis of the Advance Trial in Vietnam
Introduction: ADVANCE was a large, multinational clinical study conducted over 5 years in type 2 diabetes mellitus (T2DM). In all, 11,140 patients were randomly assigned to receive gliclazide-based intensive glucose control (IGC) or standard glucose control (SGC). IGC was shown to significantly reduce the incidence of major macrovascular and microvascular events (composite endpoint) or major microvascular events compared with SGC, primarily by en…
Clinical endpoint (1 work) · Cohort (1 work) · Confidence interval (1 work) · Cost effectiveness (1 work) · Cumulative incidence (1 work) · Dapagliflozin (1 work) · Diabetes Management and Research (1 work) · Diabetes mellitus (1 work) · Diabetes Treatment and Management (1 work) · Diabetes, Cardiovascular Risks, and Lipoproteins (1 work)